| 17-Hydroxyprogesterone Caproate | Placebo |
---|---|---|
 | (N = 4) | (N = 8) |
Maternal Management & Complications | 3 (75%) | 7 (87.5%) |
   Tocolysis in first 48 h | 3 (75%) | 5 (62.5%) |
   Antenatal Corticosteroids | 4 (100%) * | 8 (100%) |
   Cesarean Delivery | 3 (75%) | 5 (62.5%) |
   Preeclampsia or Gestational Hypertension | 0 | 1 (12.5%) |
   Gestational Diabetes | 0 | 2 (25%) |
   Chorioamnionitis | 1 (25%) | 1 (12.5%) |
   Sepsis | 0 | 0 |
Neonatal Outcomes | ||
   Birthweight, gms | 1328 ± 547 | 1288 ± 525 |
   Total Hospital Stay, Days | 42 ± 23 | 57 ± 48 |
   NICU Stay, Days | 42 ± 23 | 56 ± 48 |
   Newborns with Congenital Anomaly** | 1 (25%) | 3 (37.5%) |
   Adverse Events Not Tabulated Elsewhere*** | 0 | 1 (12.5%) |